SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Cervical Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Cervical Cancer.

GSK offers glimpse at positive Phase 3 antibiotic data for urogenital gonorrhea

Two months after its urogenital gonorrhea antibiotic hit the primary endpoint in a registrational trial, GSK is providing a closer look at results as it

April 18, 2024

Experts recommend cascade screening over universal lipid screening for familial hypercholesterolemia

The German Institute for Quality and Efficiency in Health Care (IQWiG) was commissioned by the Federal Joint Committee (G-BA) to assess the benefit of universal

November 21, 2024

Vir antibody drug aimed at influenza A fails in clinical trial

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person

July 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.